AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's DiseasePRNewsWire • 09/20/21
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisPRNewsWire • 09/16/21
2 Yield Traps To Avoid And 2 High-Yield Aristocrats That Will Make Retirees OverjoyedSeeking Alpha • 09/16/21
AbbVie Inc. (ABBV) CEO Rich Gonzalez Presents at Morgan Stanley Virtual 19th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/15/21
AbbVie's deal to develop Regenxbio's investigational gene therapy could be worth $1.8 billionMarket Watch • 09/13/21